A New Pathway to Beta Cells

Innovative process could increase beta cell supply for type 1 diabetes research and encapsulated cell replacement products An important new technique to more rapidly convert human embryonic stem cells (hESCs) into cells similar to pancreatic beta cells was reported recently in Nature Biotechnology. In a study partially funded by JDRF, Dr. Timothy Kieffer of the […]

Unlocking Type 1 Diabetes Data

JDRF partners with Tidepool on data integration software for better type 1 diabetes management JDRF is partnering with the non-profit organization Tidepool to develop a new data integration tool for people with type 1 diabetes (T1D) who use insulin pumps, continuous glucose monitors, or blood glucose meters. The new tool at the center of the […]

A Gut Reaction to Type 1 Diabetes

JDRF consortium defines roadmap for testing potential links between gut microbes and type 1 diabetes One of the first questions a person or parent of a child diagnosed with type 1 diabetes (T1D) often asks is, “what caused this?” While we have learned a lot about T1D, we still do not have a simple answer […]

A New Switch Hitter for Type 1 Diabetes Discovered

Pancreatic cells are more adaptable and possess a greater potential for self-healing than previously assumed For decades, the prevailing wisdom was that beta cells could not regenerate and that their loss in type 1 diabetes (T1D) was irreversible—the reason why people with T1D require insulin injections for life. JDRF-funded research is helping rewrite the textbook […]

Research Teamwork is Key to Curing Type 1 Diabetes

JDRF takes center stage at Capitol Hill briefing on accelerating biomedical research progress Richard A. Insel, M.D., JDRF’s Chief Scientific Officer, joined other research leaders at a Congressional briefing on, “How the Research-by-Consortia Model Will Lead to Faster Cures” held recently in Washington D.C. The briefing brought together biomedical leaders from foundations, industry, government, and […]

JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

Updated Sept. 18, 2014 JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]

Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Cocktail Immune Therapy Beats Going Solo

New clinical results show positive effect of combination immune therapy for type 1 diabetes Type 1 diabetes (T1D) is caused when the immune system mistakenly attacks insulin-producing beta cells within the pancreas. While there have been numerous clinical studies using general immunotherapy to stop or slow the T1D attack, researchers have been generally disappointed with […]